Production (Stage)
Boundless Bio, Inc.
BOLD
$1.05
-$0.04-3.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 38.60% | 46.78% | 39.84% | 61.39% | 45.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.71% | 32.49% | 25.16% | 38.90% | 39.68% |
| Operating Income | -2.71% | -32.49% | -25.16% | -38.90% | -39.68% |
| Income Before Tax | -2.13% | -35.44% | -25.32% | -36.93% | -31.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.13% | -35.44% | -25.32% | -36.93% | -31.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.13% | -35.44% | -25.32% | -36.93% | -31.67% |
| EBIT | -2.71% | -32.49% | -25.16% | -38.90% | -39.68% |
| EBITDA | -2.43% | -32.72% | -25.38% | -39.38% | -40.25% |
| EPS Basic | 94.24% | 92.45% | 93.07% | 92.50% | -23.82% |
| Normalized Basic EPS | 94.24% | 92.45% | 93.07% | 92.50% | -23.82% |
| EPS Diluted | 94.24% | 92.45% | 93.07% | 92.50% | -23.82% |
| Normalized Diluted EPS | 94.24% | 92.45% | 93.07% | 92.50% | -23.82% |
| Average Basic Shares Outstanding | 1,672.66% | 1,692.76% | 1,709.27% | 1,726.12% | 6.34% |
| Average Diluted Shares Outstanding | 1,672.66% | 1,692.76% | 1,709.27% | 1,726.12% | 6.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |